Metabolic Modulation Enhances Ferroptosis and Cuproptosis in Tumors

Study Background and Research Question

Cell death pathways such as apoptosis, ferroptosis, and the more recently described cuproptosis are central to the development of effective cancer therapies. While apoptosis inducers have long dominated the field, accumulating evidence underscores the importance of regulated cell death (RCD) modes like ferroptosis—an iron-dependent, lipid peroxidation-driven process—and cuproptosis, a copper-dependent pathway involving mitochondrial protein aggregation. The interplay between these RCD processes is of particular interest in oncology, where resistance to single-pathway targeting often limits therapeutic efficacy. The reference study (Chemical Engineering Journal 500 (2024) 156732) addresses the central question: Can metabolic intervention be used to synchronously enhance tumor cell susceptibility to both ferroptosis and cuproptosis, thereby improving anti-tumor outcomes?

Key Innovation from the Reference Study

The innovation lies in the design of a composite nanosystem (SCu/L) that delivers a glycolysis and NAD⁺ metabolism inhibitor (STF-31) within a copper-tannic acid liposomal network. This platform achieves dual modulation: it increases intracellular copper ion accumulation (triggering cuproptosis) while simultaneously depleting key metabolic intermediates required for glutathione (GSH) synthesis and antioxidant defense (sensitizing cells to ferroptosis). By orchestrating this dual stress, the system overcomes limitations of previous cuproptosis or ferroptosis inducers, which often suffered from rapid clearance, low tumor selectivity, or inability to induce both forms of cell death concurrently. The result is a metabolic intervention strategy that enhances RCD susceptibility while also modulating the tumor immune microenvironment (TIME) to potentiate anti-tumor immunity (reference study).

Methods and Experimental Design Insights

The research team engineered the SCu/L nanosystem by encapsulating STF-31 in a lipid bilayer containing a copper-tannic acid (Cu-TA) composite. STF-31 inhibits both glycolysis and compensatory NAD⁺ metabolic pathways, reducing the pools of glucose, NAD⁺, NADPH, and ATP within cancer cells. This depletion directly impairs GSH synthesis—critical for cellular antioxidant capacity—and inactivates Cu-ATPases, thereby suppressing copper efflux and enhancing mitochondrial copper accumulation.

Key experimental approaches included:

• Characterization of the nanosystem’s physicochemical properties and copper-loading efficiency.
• Assessment of intracellular ATP, NAD⁺, and GSH levels post-treatment in tumor cell lines.
• Evaluations of ferroptosis and cuproptosis markers after SCu/L administration, including mitochondrial protein aggregation and lipid peroxidation assays.
• In vivo studies to monitor anti-tumor efficacy, immune infiltration, and indicators of immunogenic cell death.

This multifaceted design allowed the authors to dissect the roles of metabolic inhibition and copper accumulation in driving tumor-selective RCD.

Core Findings and Why They Matter

The SCu/L nanosystem achieved several key outcomes:

• Potentiation of ferroptosis and cuproptosis: Tumor cells treated with SCu/L showed reduced GSH and ATP, increased mitochondrial copper, and heightened markers of both ferroptosis (e.g., lipid peroxidation) and cuproptosis (e.g., aggregation of lipoylated mitochondrial enzymes).
• Remodeling of the tumor immune microenvironment: Glycolysis inhibition not only promoted RCD but also reprogrammed the TIME, leading to enhanced T cell infiltration and immunogenic cell death.
• Boosted anti-tumor immunity: In vivo, the combined metabolic and copper stress resulted in significantly improved tumor suppression compared to controls or single-pathway interventions (study findings).

This dual-sensitization strategy addresses a major gap in the field: the challenge of achieving robust, multi-modal cell death in tumors with complex resistance profiles. By leveraging metabolic vulnerabilities, the approach provides a blueprint for next-generation cancer research compounds that act as both apoptosis and autophagy inducers, while also serving as antiproliferative agents.

Comparison with Existing Internal Articles

Several internal resources complement and contextualize these findings. For example, "DeferoxamineB as a Precision Tool for Ferroptosis and Cuproptosis Research" discusses the utility of Deferoxamine (DeferoxamineB) as a potent iron chelator for modulating ferroptosis and cuproptosis in vitro. Unlike the referenced nanosystem, Deferoxamine operates primarily through iron sequestration, reducing available Fe(III) and limiting iron-catalyzed lipid peroxidation, thus providing precise control over ferroptotic pathways. Additionally, the article "DeferoxamineB: Iron Chelation and Apoptosis Induction Benchmarks" details Deferoxamine’s role as an apoptosis and autophagy inducer, highlighting its broad value in cancer research and its overlap with the dual-pathway RCD strategy explored in the reference study.

While the metabolic intervention described in the reference paper integrates both copper and metabolic targeting, the internal workflows using Deferoxamine emphasize the importance of iron chelation and oxidative stress modulation—pointing toward converging research directions in RCD-based oncology strategies.

Limitations and Transferability

The study’s nanosystem offers strong preclinical evidence for dual-mode RCD induction, but several limitations should be considered before broader application. First, the complexity of the SCu/L platform—requiring precise nanoparticle formulation and tumor-targeted delivery—may pose translational challenges. The specificity of metabolic inhibition and copper accumulation in heterogeneous tumor microenvironments requires further validation in diverse cancer models and eventual clinical settings. Additionally, while the metabolic-cuproptosis-ferroptosis axis is compelling, questions remain about long-term toxicity, off-target effects, and the durability of anti-tumor immunity in vivo.

Protocol Parameters

• SCu/L nanosystem preparation: Encapsulate STF-31 within a Cu-tannic acid-liposome network; optimize copper loading and nanoparticle stability as described in the reference study’s supplementary methods.
• In vitro metabolic intervention: Treat cancer cell lines with SCu/L at concentrations that achieve significant reduction in intracellular GSH and NADPH within 24–48 hours.
• Ferroptosis/cuproptosis marker assessment: Monitor lipid peroxidation, mitochondrial protein aggregation, and cell viability using established imaging and biochemical assays.
• In vivo efficacy and immune profiling: Administer SCu/L via intravenous injection in murine tumor models; evaluate tumor growth inhibition, T cell infiltration, and ICD markers at defined timepoints.
• Deferoxamine workflows: For comparison and combinatorial studies, Deferoxamine (DeferoxamineB) can be used at concentrations ≥6 mg/mL in water, following iron chelator storage guidelines at -20°C (product information).

Research Support Resources

For researchers seeking to replicate or extend these findings, Deferoxamine (DeferoxamineB) from APExBIO (SKU BA2746) offers a well-characterized iron chelator suitable for modulation of ferroptosis and related cell death pathways. Its solubility and storage properties facilitate use in both biochemical assays and cell culture studies, complementing metabolic intervention strategies. Additional workflow guidance and troubleshooting protocols can be found in internal resources such as "DeferoxamineB in Cancer Research: Protocols, Workflows, and Troubleshooting".